Pacer Advisors
STML

Pacer Advisors’s Stemline Therapeutics, Inc. STML Stock Holding History

Pacer Advisors’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,143
Closed -$36K – 1157
2018
Q3 		$36K Buy
+2,143
New +$34.4K ﹤0.01% 1157

Other funds holding STML

PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Pacer Advisors's STML Position: Q4 2018 in Review

Pacer Advisors sold out of Stemline Therapeutics, Inc. (STML) in Q4 2018, closing a stake of 2,143 shares — an estimated $36K sold.

Pacer Advisors first reported a position in STML in Q3 2018 and held it in 1 quarter. The position peaked at $36K in Q3 2018. 92 funds tracked by Wall St. Rank hold STML as of Q4 2018.

  • Pacer Advisors reported no remaining Stemline Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • Pacer Advisors sold 2,143 Stemline Therapeutics, Inc. shares in Q4 2018, an estimated $36K.
  • Pacer Advisors first reported a position in Stemline Therapeutics, Inc. in Q3 2018 and held it in 1 quarter.
  • Pacer Advisors's Stemline Therapeutics, Inc. position peaked at $36K in Q3 2018.
  • 92 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2018.

Based on Pacer Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.